28 November 2022
Investments in the production of Russian substances for medicines for 10 plants (to be launched starting from 2023) may amount to 50 billion rubles, Deputy Minister of Industry and Trade Vasily Osmakov told the media. The statement was made at the interregional economics and energy industry forum in Volgograd.
“We receive the main volume of supplies (pharmaceutical substances) from India and China, which are friendly countries. These deliveries have not stopped. Meanwhile, in parallel, we are launching a project on import substitution of substances. It is called “Russia’s Substances”. This involves about 50 billion investments, starting next year, for 10 plants that will produce substances,” TASS quotes Osmakov.
According to him, the production and development of vaccines against coronavirus and influenza continue all the time.
“This is because strains change all the time, and we have always wanted to make a polyvalent vaccine from everything that we deal with, so that one injection protects from several strains of influenza, and even COVID, for good measure,” said the deputy head of the Ministry of Industry and Trade.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024